

### **Pubblicazioni più rilevanti (ultimi 5 anni)**

1. Cappelletti V, Miodini P, Reduzzi C, Alfieri S, Daidone MG, Licitra L, Locati LD. Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells. *Ann Oncol.* 2018 Jul 1;29(7):1598-1600.
2. Cappelletti V, Iorio E, Miodini P, Silvestri M, Dugo M, Daidone MG. Metabolic Footprints and Molecular Subtypes in Breast Cancer. *Dis Markers.* 2017;2017:7687851.
3. Callari M, Dugo M, Miodini P, Veneroni S, Bianchini G, Daidone MG, Cappelletti V. Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. *Int J Mol Sci.* 2018 Jan 9;19(1). pii: E196.
4. Merlino G, Miodini P, Callari M, D'Aiuto F, Cappelletti V, Daidone MG. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer. *Mol Oncol.* 2017 Oct;11(10):1399-1412.
5. Reduzzi C, Motta R, Bertolini G, Miodini P, Martinetti A, Sottotetti E, Daidone MG, Cappelletti V. Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. *Adv Exp Med Biol.* 2017;994:83-103.
6. Appierto V, Di Cosimo S, Reduzzi C, Pala V, Cappelletti V, Daidone MG. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. *Semin Cancer Biol.* 2017 Jun;44:106-116.
7. Fina E, Necchi A, Giannatempo P, Colecchia M, Raggi D, Daidone MG, Cappelletti V. Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. *Bladder Cancer.* 2016 Oct 27;2(4):395-403.
8. Callari M, Guffanti A, Soldà G, Merlino G, Fina E, Brini E, Moles A, Cappelletti V, Daidone MG. In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays. *Oncotarget.* 2016 Jan 5;7(1):976-94.
9. Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. *Clin Cancer Res.* 2016 Jan 15;22(2):337-45.
10. Fina E, Reduzzi C, Motta R, Di Cosimo S, Bianchi G, Martinetti A, Wechsler J, Cappelletti V, Daidone MG. Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer. *Int J Biol Markers.* 2015 Nov 11;30(4):e429-33.
11. D'Aiuto F, Callari M, Dugo M, Merlino G, Musella V, Miodini P, Paolini B, Cappelletti V, Daidone MG. miR-30e\* is an independent subtype-specific prognostic marker in breast cancer. *Br J Cancer.* 2015 Jul 14;113(2):290-8.
12. Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. *Biomed Res Int.* 2015;2015:731479.
13. Musella V, Callari M, Di Buduo E, Scuro M, Dugo M, Miodini P, Bianchini G, Paolini B, Gianni L, Daidone MG, Cappelletti V. Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients. *PLoS One.* 2015 Apr 6;10(4):e0123194.
14. Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I, Maggi C, Di Bartolomeo M, de Braud F, Daidone MG, Cappelletti V. Circulating tumor cells as a longitudinal

biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. *Int J Cancer*. 2015 Sep 15;137(6):1467-74.

15. Fina E, Callari M, Reduzzi C, D'Aiuto F, Mariani G, Generali D, Pierotti MA, Daidone MG, Cappelletti V. Gene expression profiling of circulating tumor cells in breast cancer. *Clin Chem*. 2015 Jan;61(1):278-89.
16. Angeloni V, Tiberio P, Appierto V, Daidone MG. Implications of stemness-related signaling pathways in breast cancer response to therapy. *Semin Cancer Biol*. 2015 Apr;31:43-51.
17. Callari M, Musella V, Di Buduo E, Sensi M, Miodini P, Dugo M, Orlandi R, Agresti R, Paolini B, Carcangiu ML, Cappelletti V, Daidone MG. Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. *Mol Oncol*. 2014 Oct;8(7):1278-89.